Jump to main content
Jump to site search

Issue 21, 2014
Previous Article Next Article

Quantification of an exogenous cancer biomarker in urinalysis by Raman Spectroscopy

Author affiliations

Abstract

We quantified an exogenous cancer biomarker, Acetyl amantadine (AcAm), directly from urine solution using surface enhanced Raman spectroscopy (SERS). SERS was used for the detection of AcAm using a commercial Raman substrate after beta-cyclodextrin encapsulation for capture of the analyte. We achieved a detection limit of 1 ng mL−1 of AcAm in the mock urine in the absence of steroids without extraction or other pre-treatment methods required. With levels of corticosterone typical of urine, the limit of detection was 30 times higher. Since the approach works directly from samples containing the high concentrations of salts and organic co-solutes normal to urine, it has the potential to reduce cost and speed up processing with respect to methods that require pre-purification. Therefore, this is promising for clinical adoption for early cancer detection, particularly for lung cancer.

Graphical abstract: Quantification of an exogenous cancer biomarker in urinalysis by Raman Spectroscopy

Back to tab navigation

Supplementary files

Publication details

The article was received on 19 Jul 2014, accepted on 19 Aug 2014 and first published on 19 Aug 2014


Article type: Paper
DOI: 10.1039/C4AN01309C
Author version
available:
Download author version (PDF)
Citation: Analyst, 2014,139, 5375-5378
  •   Request permissions

    Quantification of an exogenous cancer biomarker in urinalysis by Raman Spectroscopy

    G. Cao, G. Hajisalem, W. Li, F. Hof and R. Gordon, Analyst, 2014, 139, 5375
    DOI: 10.1039/C4AN01309C

Search articles by author

Spotlight

Advertisements